Virginia Falvello1, Catherine Van Poznak2. 1. Department of Internal Medicine, University of Michigan, 1500 East Medical Center Dr, Ann Arbor, MI, 48109, USA. 2. Department of Internal Medicine, University of Michigan, 1500 East Medical Center Dr, Ann Arbor, MI, 48109, USA. cvanpoz@med.umich.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to highlight novel and impactful discoveries in systemic treatment of bone metastatic disease in solid tumors published within the past 5 years. RECENT FINDINGS: Major developments in systemic treatment of bone metastatic disease in solid tumors include evidence that decreasing frequency of dosing zoledronic acid in metastatic breast and prostate cancer maintains efficacy in preventing skeletal-related events while decreasing costs. The landmark findings on the use of Radium-223 to treat metastatic prostate cancer were reported in 2013. Recently, it has been found that not all systemic therapy combinations with Radium-223 are necessarily safe or effective unless bone-targeted therapy is also included in the regimen. More cost-effective dosing intervals of zoledronic acid and efficacy and safety nuances of combination radiopharmaceutical and chemotherapy treatment have been better delineated.
PURPOSE OF REVIEW: The purpose of this review is to highlight novel and impactful discoveries in systemic treatment of bone metastatic disease in solid tumors published within the past 5 years. RECENT FINDINGS: Major developments in systemic treatment of bone metastatic disease in solid tumors include evidence that decreasing frequency of dosing zoledronic acid in metastatic breast and prostate cancer maintains efficacy in preventing skeletal-related events while decreasing costs. The landmark findings on the use of Radium-223 to treat metastatic prostate cancer were reported in 2013. Recently, it has been found that not all systemic therapy combinations with Radium-223 are necessarily safe or effective unless bone-targeted therapy is also included in the regimen. More cost-effective dosing intervals of zoledronic acid and efficacy and safety nuances of combination radiopharmaceutical and chemotherapy treatment have been better delineated.
Authors: C Parker; E Castro; K Fizazi; A Heidenreich; P Ost; G Procopio; B Tombal; S Gillessen Journal: Ann Oncol Date: 2020-06-25 Impact factor: 32.976
Authors: S Novello; F Barlesi; R Califano; T Cufer; S Ekman; M Giaj Levra; K Kerr; S Popat; M Reck; S Senan; G V Simo; J Vansteenkiste; S Peters Journal: Ann Oncol Date: 2016-09 Impact factor: 32.976
Authors: Catherine Van Poznak; Mark R Somerfield; William E Barlow; J Sybil Biermann; Linda D Bosserman; Mark J Clemons; Sukhbinder K Dhesy-Thind; Melissa S Dillmon; Andrea Eisen; Elizabeth S Frank; Reshma Jagsi; Rachel Jimenez; Richard L Theriault; Theodore A Vandenberg; Gary C Yee; Beverly Moy Journal: J Clin Oncol Date: 2017-10-16 Impact factor: 44.544
Authors: Kevin P Weinfurt; Liana D Castel; Yun Li; Justin W Timbie; G Alastair Glendenning; Kevin A Schulman Journal: Med Care Date: 2004-02 Impact factor: 2.983
Authors: Dino Amadori; Massimo Aglietta; Barbara Alessi; Lorenzo Gianni; Toni Ibrahim; Gabriella Farina; Fernando Gaion; Francesco Bertoldo; Daniele Santini; Roberta Rondena; Paola Bogani; Carla I Ripamonti Journal: Lancet Oncol Date: 2013-05-16 Impact factor: 41.316